SML2808
Sparsentan
≥98% (HPLC)
别名:
2-[4-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide, 4′-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2′-(ethoxymethyl)[1,1′-biphenyl]-2-sulfonamide, BMS-346567, BMS346567, RE-021
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
2-8°C
SMILES字符串
[S](=O)(=O)(Nc5n[o]c(c5C)C)c1c(cccc1)c2c(cc(cc2)CN3C(=O)C4(NC3=CCCC)CCCC4)COCC
InChI key
OIBXMWCQTPVHKR-UHFFFAOYSA-N
生化/生理作用
Sparsentan (BMS346567) is an orally available and highly potent dual antagonist of angiotensin II AT1 receptor and endothelin A ETA receptor. It is an analog of BMS-248360 that is orally available in rats and higher species.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
从最新的版本中选择一种:
Journal of the American Society of Nephrology : JASN, 29(11), 2745-2754 (2018-10-27)
We evaluated and compared the effects of sparsentan, a dual endothelin type A (ETA) and angiotensin II type 1 receptor antagonist, with those of the angiotensin II type 1 receptor antagonist irbesartan in patients with primary FSGS. In this phase
Journal of medicinal chemistry, 48(1), 171-179 (2005-01-07)
In a previous report we demonstrated that merging together key structural elements present in an AT(1) receptor antagonist (1, irbesartan) with key structural elements in a biphenylsulfonamide ET(A) receptor antagonist (2) followed by additional optimization provided compound 3 as a
Kidney international reports, 2(4), 654-664 (2017-11-17)
Primary focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. There are no US Food and Drug Administration-approved therapies for FSGS, and treatment often fails to reduce proteinuria. Endothelin is an important factor in
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门